Details of the Drug Combinations

General Information of This Drug (ID: DMQ1Q37)

Drug Name

Megesterol acetate DMQ1Q37

Indication

Disease Entry	ICD 11	Status	REF
Atypical endometrial hyperplasia	N.A.	Approved	[1]
Breast cancer	2C60-2C65	Approved	[2]
Endometrial carcinoma	N.A.	Investigative	[3]
------------------------------------------------------------------------------------

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Megesterol acetate + Idarubicin	DCTSBPP	Idarubicin	Glioblastoma? (Cell Line: T98G)	[4]
------------------------------------------------------------------------------------

References

1	Fertility-sparing management for endometrial cancer: review of the literature. Minerva Med. 2021 Feb;112(1):55-69.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Megestrol acetate drives endometrial carcinoma cell senescence via interacting with progesterone receptor B/FOXO1 axis. Exp Biol Med (Maywood). 2021 Nov;246(21):2307-2316.
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.